bioavailability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
During the visit to the archives, Xi said that "over the past 250 years, the American people have pursued the American Dream and built a prosperous country and a beautiful home on the North American continent" while "Chinese people, inheriting 5,000 years of Chinese civilization, have continued to make new achievements on the new journey toward realizing the Chinese Dream of the great rejuvenation of the Chinese nation". He said while "China and the United States have different histories and cultures, social systems and development paths", the "people of the two countries share the same aspiration for a better life despite the differences". Trump told reporters that "We’re just comparing. Ours goes 250 years. Which is great, and we’re proud of. Theirs goes 6,000 years. So there’s a little difference between 6,000 and 250. But we’re very proud of our 250." Before the visit finished, Trump gifted Xi a photo album of the trip. Afterwards, Xi and Peng left for Joint Base Andrews for their red carpet departure, with representatives of overseas Chinese and international students waving the Chinese and American flags on the road to on way to the airport. Senior US government officials saw them off at the airport, and a 21-gun salute was fired. They then onboarded a plane bound for Beijing, concluding the state visit. They returned to China on the afternoon of September 26.
=== Hospitals === Most clinical teaching takes place in facilities operated by UNC Health, primarily within the UNC Medical Center complex at the southern tip of the UNC campus. The complex comprises five healthcare facilities collectively known as UNC Hospitals, including North Carolina Memorial Hospital, North Carolina Children’s Hospital, North Carolina Women’s Hospital, North Carolina Neurosciences Hospital, and North Carolina Cancer Hospital. In 2024, the North Carolina Surgical Hospital was opened, featuring 26 new surgical spaces and 80 inpatient rooms. Together, these facilities offer over 1,000 inpatient beds and are ranked as the 2nd best hospital in the state of North Carolina. Additional hospitals and outpatient clinics in the area are also used for training, including the Ambulatory Care Center, the Family Medicine Building, UNC Hillsborough, and UNC Chatham. During the Application Phase (third year) of the school's MD program, students will be matched into one of six regions located across the state of North Carolina to complete their clinical clerkships at local facilities, including:
The relatively recent emergence of Salvia divinorum in modern Western culture, in comparison to its long continuing traditions of Indigenous use, contrasts widely differing attitudes on the subject. Opinions range from veneration of the plant as a spiritual sacrament or "a gift from the gods" to a "threat to society," to be banned as quickly as possible in order to "spare countless families the horror of losing a loved one to the relentless tentacles of drug abuse".
Sources: en.wikipedia.org
Smuts informed the General Assembly that it had already been so thoroughly incorporated with South Africa a UN-sanctioned annexation was no more than a necessary formality. The Smuts delegation's request for the termination of the mandate and permission to annex South West Africa was not well received by the General Assembly. Five other countries, including three major colonial powers, had agreed to place their mandates under the trusteeship of the UN, at least in principle; South Africa alone refused. Most delegates insisted it was undesirable to endorse the annexation of a mandated territory, especially when all of the others had entered trusteeship. Thirty-seven member states voted to block a South African annexation of South West Africa; nine abstained. In Pretoria, right-wing politicians reacted with outrage at what they perceived as unwarranted UN interference in the South West Africa affair. The National Party dismissed the UN as unfit to meddle with South Africa's policies or discuss its administration of the mandate. One National Party speaker, Eric Louw, demanded that South West Africa be annexed unilaterally. During the South African general election, 1948, the National Party was swept into power, newly appointed Prime Minister Daniel Malan prepared to adopt a more aggressive stance concerning annexation, and Louw was named ambassador to the UN. During an address in Windhoek, Malan reiterated his party's position that South Africa would annex the mandate before surrendering it to an international trusteeship.
== Structure == Delta hexatoxin Hv1 is a tightly folded polypeptide that contains a chain of 42 amino acid residues and has the chemical formula C206H318N58O60S9. The amino acid sequence of delta hexatoxin Hv1 is:The tertiary structure of δ-ACTX-Hv1 contains a core β region that is made up of the residues Cys1–Cys8, Cys14–Val21, and Ser30–Ser33, with Tyr22–Gly29 protruding outwards. The β region has a three-stranded antiparallel β sheet comprising Asn6–Trp7 (β1), Met18–Val21 (β2), and Ser30–Ser33 (β3). The C-terminal end of the short β1 is held in place by a bifurcated hydrogen bond between the Cys8 amide proton and the carbonyl oxygens of the two residues preceding β strand 3 (Gln28 and Gly29). The β region also contains type II β turns at Lys3–Asn6 and Cys15–Met18 with a rare cis peptide bond at Cys16–Met 17. The nonpolar C-terminal 310 helix formed by Ile35–Lys41, bordering Lys40 and Lys41 and connecting to β region with a disulphide bond next to a β turn. The β region contains hydrophobic cysteine sidechains bordered by a lysine sidechain.Three of the four disulphide bonds form the ICK. The structure of the cystine knot motif found in versutoxin is similar to the one found in gurmarin, a 35-residue plant polypeptide used to test the inhibition of sweet taste receptors.
Gastroptosis is the abnormal downward dislocation (ptosis) of the stomach in which its greater curve is displaced below the iliac crest. The stomach is often elongated. The condition frequently causes digestive symptoms, epigastric pain, constipation, gastric reflux, nausea, decreased appetite, gastroparesis (delayed gastric emptying), and in severe cases Median arcuate ligament syndrome. It is much more prominent in women than men, and is diagnosed with x-ray using barium contrast. Gastroptosis is mainly caused by the relaxation of surrounding ligaments and mesenteries as a result of the weight of the stomach and may be due to genetic connective tissue disease.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.